Comments
Drug firm AstraZeneca Pharma on Monday said it has received marketing authorisation from the Drug Controller General of India for Benralizumab solution, indicated as an add-on maintenance treatment for severe asthma.
AstraZeneca Pharma India Ltd has received import and market permission in Form CT-20 (marketing authorisation) from the Drugs Controller General of India for Benralizumab 30mg/ml solution for injection (Fasenra), the drug firm said in a regulatory filing. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
AstraZeneca Pharma said the receipt of this permission paves the way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.
Shares of AstraZeneca Pharma India were trading 1.22 per cent higher at ₹4,936.05 apiece on the BSE in morning trade.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.